Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including ...

Get the skinny on getting skinny. — -- Just in time for swimsuit season, a new study has come out saying there's very little scientific evidence to prove most diet and weight-loss regimens ...

Matching weight loss tools to the dominant drivers of weight regulation can lead to more effective, durable, and personalized ...

If you’ve ever Googled “best weight loss program,” you know the options are endless—and overwhelming. From meal delivery to macro tracking, it can be hard to know which approach actually works, and ...

Doctors and groups representing employers said they’re increasingly hearing about companies cutting weight loss drugs out of ...

Health care leaders and professionals constantly seek ways to improve their clients’ lifestyles. In recent times, nutritional programs have emerged as a tool that provides a balanced diet to drive ...

MALAGA, Spain—Patients with obesity treated with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy; Novo Nordisk) can achieve weight loss in the real world similar to what has ...

Low-income Californians who use Wegovy and similar weight loss drugs will lose their coverage in January. California and ...

Some Medicare enrollees may soon be able to access super-popular drugs for obesity under a voluntary model program, the Centers for Medicare and Medicaid Services announced Tuesday. Eligible ...

Costly GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and Zepbound could be covered under the new plan A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the ...